Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > BUSINESS
BUSINESS
- Astellas Logs Sales of 25.5 Bil. Yen in Oncology Sector, Investments Bearing Fruit: Pres. Hatanaka
November 5, 2012
- Shionogi Enjoys Sales, Profit Growth in 1st Half, 8 Strategic Products Make Up 50% of Japan Sales
November 5, 2012
- Domestic Drug Makers’ Major Products See Sharp Declines in 1st Half; Sales of Aricept, Lipitor Down 30%
November 5, 2012
- Eisai to Go on Offensive for Aricept by Introducing Consultation Date Reminder Service for Patients: President Naito
November 5, 2012
- Astellas Discontinues Development of SGLT-2 Inhibitor Ipragliflozin in Europe, US; Development in Japan to Go Forward
November 5, 2012
- Astellas: Slight Sales Decline in 1st Half due to Strong Yen, Domestic Sales Virtually Unchanged
November 5, 2012
- “Lecture Meeting Fever” as Companies Seek New Ways to Interact with Doctors Under Tougher Restrictions on Settai
November 5, 2012
- Medipal HD Reports Sharp Increase in Operating Profits in First Half
November 2, 2012
- Eisai Suffers Double-Digit Sales, Profit Falls in 1st Half as Mainstay Drugs Slump
November 2, 2012
- Sales Target for Prasugrel Achievable Despite Add’l Indication Dropped: Daiichi Sankyo Pres. Nakayama
November 2, 2012
- Shionogi Licenses Alzheimer’s Disease Treatment to Janssen Pharmaceuticals of US
November 2, 2012
- DSP’s 1st Half Sales Up Mere 0.4 % due to Stagnant Domestic Sales, Profits Show Double-Digit Increase
November 2, 2012
- Takeda’s 1st Half Operating Profits Down 48% due to M&A Costs
November 1, 2012
- FDA Accepts Supplemental NDAs for Latuda for Bipolar Depression: DSP
November 1, 2012
- Takeda’s Japan Sales Ratio Likely to Fall to Mid-30% Range: President Hasegawa
November 1, 2012
- EpiPen Marketing Approval Transferred to Pfizer from Mylan
November 1, 2012
- Daiichi Sankyo’s Semiannual Sales Up 6.2% Driven by Ranbaxy
November 1, 2012
- Japanese Pharmaceutical Industry Should Speak More Strongly in Favor of TPP: Paul King
November 1, 2012
- Bayer Announces Positive Results of PIII Trials of Riociguat in Patients with CTEPH, PAH
October 31, 2012
- Mochida, MTPC See Signs of Sales Growth for Lexapro after Lifting of Long-Term Prescription Ban
October 31, 2012
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…